Checkpoint inhibitors in relapsed refractory Hodgkin Lymphoma

Podcast 2021012
Download attendance certificate
e-ESO podcast channel
Listen on Spotify
Listen on Apple
Listen on Google

Questions:

  1. Why do chemorefractory patients respond to checkpoint inhibitors?
  2. Can you comment on the design and results of the KEYNOTE 204 for patients with RR HL?
  3. What do you think are the future challenges and therapeutic options in this group of patients?
Expert
Astrid Pavlovsky'
Astrid Pavlovsky
Clinical Research Center - FUNDALEU
Buenos Aires, Argentina
27
May 2021
Download attendance certificate
e-ESO podcast channel
Listen on Spotify
Listen on Apple
Listen on Google
Related e-Sessions:
ESCO logo
ESCO is the College of the European School of Oncology for ESO students offering a structured educational pathway to enhance their oncology careers.
Ulm university
Ulm university
The e-ESO e-Sessions are part of the Master-Online Study Program Advanced Oncology of Ulm University
www.uni-ulm.de
The mastermind winners of
e-Session 660
  1. Reda Mohamed Husseen
  2. Marina Puchinskaya
  3. Zacharoula Sidiropoulou
ESO & OncoAlert
e-Eso Onco alert
Oncology education together via social media
facebook eso twitter eso instagram eso